Skip Navigation

Citi says buy the dip in Eli Lilly ahead of Alzheimer's drug launch

Published Wed, Sep 29 20216:36 AM EDTUpdated Wed, Sep 29 20217:16 AM EDT

Hannah Miao @hannahmiao_

Eli Lilly Pharmaceutical company logo

SOPA Images | LightRocket | Getty Images

The recent pullback in Eli Lilly's stock provides an attractive buying opportunity ahead of the company's Alzheimer's drug launch, Citi said.

More In Analyst Calls

These are Goldman Sachs' favorite stocks with 50% or more upside

These are Goldman Sachs' favorite stocks with 50% or more upside

Evercore ISI says three years of biotech underperformance may be ending, gives its 5 favorite stocks

Evercore ISI says three years of biotech underperformance may be ending, gives its 5 favorite stocks

Bank of America sees 60% upside for this software stock that's using AI to innovate

Bank of America sees 60% upside for this software stock that's using AI to innovate